Search Results
Your search for ,WhO matches 21057 pages
Showing 11051 - 11100Small Study Shows Fecal Microbiota Transplantation May Help Restore Beneficial Bacteria in Patients With Cancer
Researchers have shown that autologous fecal microbiota transplantation may be a safe and effective way to help replenish beneficial gut bacteria in patients with cancer who require intense antibiotics during allogeneic hematopoietic stem cell transplantation. Their findings were published by Taur...
Neoadjuvant Paclitaxel With LCL161 in Localized Triple-Negative Breast Cancer
In a phase II study reported in the Journal of Clinical Oncology, Bardia et al evaluated the effects of adding an antagonist of inhibitor of apoptosis proteins (LCL161) to paclitaxel as neoadjuvant therapy in patients with localized triple-negative breast cancer who did or did not have a tumor...
FDA Grants Breakthrough Therapy Designation to Rucaparib in BRCA1/2-Mutated Metastatic Castration-Resistant Prostate Cancer
The U.S. Food and Drug Administration (FDA) recently granted Breakthrough Therapy designation to rucaparib (Rubraca) monotherapy for the treatment of adult patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer who have received at least one prior androgen...
Lack of Clinical Trial Participation and Shorter Duration of Therapy Linked to Disease Relapse in AYAs With Leukemia
Despite survival gains for children diagnosed with acute lymphoblastic leukemia (ALL), adolescents and young adults (AYAs)—those between the ages of 15 and 39—diagnosed with the disease have seen only modest improvements in survival. A study by Wolfson et al in Cancer Epidemiology,...
DNA Vaccine Leads to Immune Responses in HPV-Related Head and Neck Cancer in Small Study
A therapeutic vaccine may boost antibodies and T cells, helping them infiltrate human papillomavirus (HPV)-related head and neck cancer tumors. Researchers from the Abramson Cancer Center of the University of Pennsylvania tested the immunotherapy approach in two groups of patients with...
Long-Term Outcomes With Anti–PD-L1 Treatment in Metastatic Triple-Negative Breast Cancer
In a long-term follow-up of a phase I trial reported in JAMA Oncology, Emens et al found that single-agent atezolizumab (Tecentriq) produced enduring benefit in patients with metastatic triple-negative breast cancer after stable or responding disease and in first-line treatment. Study Details In...
Conquer Cancer Podcast Series Goes Unscripted With Doctors, Patients, and Caregivers
How do patients really feel when they are in your care? What does it feel like to cure a cancer? How are the children of oncologists affected when grief is a parent’s occupational hazard? These are the personal topics explored in the candid and inspirational mini-podcast series, Your Stories:...
Cancer.Net: Trusted Information for Patients and Caregivers, Useful Tools for Providers
Cancer.Net is ASCO’s patient information website, hosting a wealth of information and resources for people diagnosed with cancer and their families and caregivers. With information on over 120 types of cancer, visitors to the site can find medical information, tips for treatment management,...
Emerging Options and Sequencing Therapy in Relapsed Multiple Myeloma
Advances in the treatment of multiple myeloma have led to longer progression-free survival, but the majority of patients will still relapse despite newer treatments. A number of new drugs and combinations are under study in the hope of improving outcomes. “Multiple myeloma is a complex disease...
Study Shows Invasive Lung Cancer Surgery Can Lead to Long-Term Opioid Use
Patients treated with more invasive surgical techniques for early-stage non–small cell lung cancer (NSCLC) are more likely to become chronic opioid users than patients treated with minimally invasive surgery, highlighting the need for additional research into how pain management after surgery ...
More to Learn About Using PARP Inhibitors for Advanced Breast Cancer With Germline BRCA Mutation
Germline mutations in the breast cancer–susceptibility genes 1 and 2 (BRCA1/2) increase the risk for cancer due to an inability to repair DNA double-strand breaks, and about 5% of patients with unselected breast cancer carry a germline BRCA mutation.1 These DNA repair–deficient tumors are...
Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome
On August 8, 2018, the CC chemokine receptor type 4 (CCR4)-directed monoclonal antibody mogamulizumab-kpkc (Poteligeo) was approved for adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy.1,2 Supporting Efficacy Data The current...
Targeting CCR4 in Cutaneous T-Cell Lymphoma: The MAVORIC Trial
The C-C chemokine receptor 4 (CCR4) is predominantly expressed in type 2 helper T (Th2) cells and regulatory T (Treg) cells.1 Under physiologic conditions and in response to its ligands, CCL17 (TARC) and CCL22 (MDC), CCR4 promotes T-cell migration to the skin.2 Of note, CCR4 is highly expressed in...
Mogamulizumab Improves Progression-Free Survival vs Vorinostat in Cutaneous T-Cell Lymphoma
As reported by Youn H. Kim, MD, of Stanford Cancer Institute, Stanford University School of Medicine, and colleagues in The Lancet Oncology, the phase III MAVORIC trial showed that the anti-C-C chemokine receptor 4 (CCR4) monoclonal antibody mogamulizumab (Poteligeo) significantly improved...
Osimertinib in First-Line Treatment of EGFR-Mutant Metastatic NSCLC
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. In April 2018, osimertinib (Tagrisso) was approved for...
Strategies for Using Anticoagulation Therapy in Patients With Cancer
Although approximately 20% to 30% of patients with cancer will develop venous thromboembolism (VTE), clinicians continue to debate strategies for pharmacologic treatment and prevention.1 At the 2018 Debates and Didactics in Hematology and Oncology Conference, held on Sea Island, Georgia, Christine...
Neuroendocrine Tumors: New Data, New Options
Because neuroendocrine tumors are not one disease but a continuum of diseases, ranging from well-differentiated tumors to poorly differentiated and small cell tumors, treatment approaches can vary greatly. At the 2018 Debates and Didactics in Hematology and Oncology conference, held on Sea Island,...
Beat AML Trial Seeking to Change Treatment Paradigm
The Beat AML Master Clinical Trial seeks to change the treatment paradigm and outcomes in acute myeloid leukemia (AML) by personalizing therapy and ultimately facilitating the approval of novel targeted agents. Co-investigator William Blum, MD, of the Winship Cancer Institute at the Emory...
Wear That White Coat—With Pride
These days it can be hard for physicians. Many in the physician workforce wonder whatever happened to the ideals and expectations that drew them to this noble profession. The genuine passion to heal the sick and infirm and in turn improve the health of the entire society The ability to touch human ...
The Relevance of the RELEVANCE Trial in Follicular Lymphoma
We have seen remarkable progress in the outcomes of patients with advanced-stage follicular lymphoma over the past 2 decades.1 Recent manuscripts and presentations describing long-term follow-up of randomized trials comparing various chemotherapy platforms (all combined with anti-CD20 antibodies)...
Update on CML: Focus on Sequential Therapy, Treatment Discontinuation, and Monitoring
Chronic myeloid leukemia (CML) is a poster child for the success of molecularly targeted therapy, with some patients appearing to be “cured” of their disease and others living for a long time after treatment with a tyrosine kinase inhibitor targeting the BCR-ABL1 protein. However, there are still...
Thermal Ablation vs Stereotactic Radiotherapy in Early-Stage NSCLC
Thermal ablation is a safe, effective treatment for early-stage non–small cell lung cancer (NSCLC), with comparable results to traditional stereotactic radiotherapy, according to a study published by Uhlig et al in the journal Radiology. The results show that ablation may be an effective ...
FDA Approves Once-Weekly Carfilzomib in Combination With Dexamethasone for Relapsed or Refractory Multiple Myeloma
Today, the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) to expand the prescribing information for carfilzomib (Kyprolis) to include a once-weekly dosing option in combination with dexamethasone (once-weekly Kd70) for patients with relapsed or...
WCLC 2018: Oncogene-Driven Patient-Caregiver Communities Creating New Paradigm for NSCLC Research
A recent review of patient-caregiver communities focused on non–small cell lung cancer (NSCLC) with genomic alterations showed that these groups are improving outcomes by supporting patients and caregivers, increasing awareness and education, and accelerating research. Patient advocate Janet...
WCLC 2018: Study Analyzes Use of Thoracic Radiotherapy for Limited-Stage SCLC
A study has demonstrated that using involved-field radiotherapy (IFRT) and irradiating postchemotherapy residual primary tumor volume for limited-stage small cell lung cancer (SCLC) did not result in increased recurrence of the cancer. Xiao Hu, MD, PhD, of the Department of Thoracic Radiotherapy,...
Cancer Vaccine Shows Clinical Benefit in Phase I Study of Patients With HER2-Positive Cancers
A preclinical study showing that a vaccination with a recombinant adenovirus expressing a truncated ErbB-2 antigen can cure advanced established murine breast cancer as well as extensive established metastatic lung cancer led to the launch of a small phase I study investigating a therapeutic cancer ...
FDA Approves Cemiplimab-rwlc for Metastatic Cutaneous Squamous Cell Carcinoma
On September 28, the U.S. Food and Drug Administration (FDA) approved cemiplimab-rwlc (Libtayo) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (SCC) or locally advanced cutaneous SCC who are not candidates for curative surgery or...
FDA Approves Dacomitinib for Metastatic Non–Small Cell Lung Cancer
On September 27, 2018, the U.S. Food and Drug Administration (FDA) approved dacomitinib tablets (Vizimpro) for the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution...
Health Resource Utilization and CNS Metastases in EGFR-Mutant Advanced NSCLC
In a single-center study reported in the Journal of Oncology Practice, Chooback et al found that central nervous system (CNS) metastases are frequent in patients with EGFR-mutant advanced non–small cell lung cancer (NSCLC) and are associated with increased health resource...
WCLC 2018: Smoking Cessation Services Widely Accepted During Lung Cancer Screening
A recent study found that smoking cessation services offered at the time of lung cancer screening had a high acceptance rate by current smokers. William Evans, MD, FRCPC, Professor Emeritus, McMaster University Department of Oncology, and clinical advisor, Smoking Cessation, Cancer Care Ontario,...
WCLC 2018: Outdoor Air Pollution Exposure and Lung Cancer in Female Never-Smokers
Findings from a recent study demonstrate that female patients with lung cancer who have never smoked have significantly greater exposure rates to outdoor air pollution than female patients with lung cancer who have a history of smoking. Renelle L. Myers, MD, FRCPC, of the British Columbia Cancer...
WCLC 2018: NELSON Study: CT Screening for Early Lung Cancer Reduces Lung Cancer Mortality
Findings from the NELSON study demonstrate that the use of computed tomography (CT) screening among asymptomatic men at high risk for lung cancer led to a 26% (95% confidence interval [CI] = 9%–41%) reduction in lung cancer deaths at 10 years of study follow-up (at 86% compliance). In the...
WCLC 2018: ALTA-1L Trial: Brigatinib vs Crizotinib in Advanced ALK-Positive NSCLC
As reported at the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer (Abstract PL02.03) and in the The New England Journal of Medicine by Camidge et al, an interim analysis of the phase III ALTA-1L trial has shown improved progression-free...
FDA Approves Duvelisib for Adult Patients With Relapsed or Refractory CLL, SLL, and Follicular Lymphoma
On September 24, 2018, the U.S. Food and Drug Administration (FDA) granted regular approval to duvelisib (Copiktra) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies. In addition, duvelisib...
David J. Sugarbaker, MD, Pioneer in Thoracic Surgery, Mesothelioma, Dies at 65
DAVID J. SUGARBAKER, MD, was an internationally recognized thoracic surgeon who specialized in the treatment of mesothelioma and complex thoracic cancers. To be recognized as first in a medical finding or procedure is a rare honor; Dr. Sugarbaker received that honor twice, being the first to...
FDA Approves Moxetumomab Pasudotox-tdfk for the Treatment of Hairy Cell Leukemia
ON SEPTEMBER 13, 2018, the U.S. Food and Drug Administration (FDA) approved moxetumomab pasudotox-tdfk (Lumoxiti) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies,...
Omission of Axillary Dissection in Early Breast Cancer
In a study reported in JAMA Oncology, Monica Morrow, MD, of the Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, and colleagues found that surgeon acceptance of more limited surgery in early breast cancer was more likely among high-volume surgeons and those preferring ...
Triplet Combination for Advanced Anal Squamous Cell Carcinoma
In a French phase II trial reported in The Lancet Oncology, Stefano Kim, MD, of the Department of Oncology, University Hospital of Besancon, and colleagues found that treatment with docetaxel, cisplatin, and fluorouracil (DCF) was active in patients with metastatic or unresectable locally...
Neoadjuvant Therapy, Changes in Body Composition, and Resectability in Pancreatic Cancer
In a retrospective cohort study reported in JAMA Surgery, Carlos Fernández-del Castillo, MD, of the Department of Surgery, Massachusetts General Hospital, Harvard Medical School, and colleagues found that neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma was associated with...
Second Allogeneic HCT vs Donor Lymphocyte Infusion in Relapsed Acute Myeloid Leukemia
In a retrospective registry study reported in JAMA Oncology, Mohamad Mohty, MD, PhD, of Hôpital Saint Antoine, Université Pierre et Marie Curie, and colleagues found no overall survival difference with second allogeneic hematopoietic cell transplantation (HCT) vs donor lymphocyte infusion (DLI) in ...
Expect Questions About Genetic Testing for Breast Cancer
A STUDY finding that pathogenic variants in 5 genes are associated with a high risk of triple-negative breast cancer and a 20% lifetime risk for overall breast cancer1 may increase interest in genetic testing. “This is the first study to establish which genes are associated with high lifetime risks ...
Mutations in Five Genes Linked to Higher Lifetime Risks for Aggressive Breast Cancer
USING MULTIGENE hereditary cancer panels to test for mutations in five genes can identify women at high risk for triple-negative breast cancer who may then benefit from more frequent screening, risk management, and potentially targeted therapies as well. A study that looked at multigene panel...
Educating Nurse Practitioners on the Care of Older Patients With Cancer in a Comprehensive Cancer Center
To expose future practitioners to the special challenges of treating cancer in older patients, the Geriatrics Service at Memorial Sloan Kettering Cancer Center (MSK) has developed a clinical education model for nurse practitioner students. Why Geriatric Oncology? GIVEN THE aging population, my...
Collaborative Effort to Raise Awareness for EGFR-Positive Lung Cancer
THE BONNIE J. ADDARIO Lung Cancer Foundation (ALCF) and the EGFR Resisters, a patient-driven community of people living with epidermal growth factor receptor (EGFR)-positive lung cancer, are working together to raise funds and increase awareness of projects that benefit the EGFR-positive cancer...
Brave Journey Home
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
R. Lor Randall, MD, FACS, Appointed Chair at UC Davis Health
R. LOR RANDALL, MD, FACS, a sarcoma surgeon and scientist, has been appointed Chair of the Department of Orthopaedic Surgery and the David Linn Endowed Chair in Orthopaedic Surgery at University of California (UC) Davis Health. In his new role, Dr. Randall leads 70 UC Davis surgeons, physicians,...
Abiraterone Acetate Plus Prednisone in High-Risk Metastatic Castration-Sensitive Prostate Cancer
IN EARLY 2018, abiraterone acetate tablets (Yonsa, Zytiga) in combination with prednisone was approved for the treatment of metastatic high-risk castration-sensitive prostate cancer.1,2 Supporting Efficacy Data APPROVAL WAS BASED on findings from the phase III LATITUDE trial, in which 1,199...
Care for the Cancer Caregiver
Providing care to patients with cancer can be overwhelming, and caregivers are at risk for physical and psychological distress, which can negatively impact their own health. Over the past decade, supporting caregiver well-being has gained prominence as a national health-care issue. In this...
Understanding the Different Perspectives on Cost and Value in Cancer Care
The estimated cost of cancer care in the United States was $125 billion in 2010 and is expected to rise to $175 billion by 2020.1 In an effort to reign in spiraling costs and deliver better care, the term “value” has become part of the new oncology lexicon, as providers, patients, and payers seek...
2018 Quality Care: New Approach Successfully Reduces Opioid Use After Urologic Oncology Surgery
In a study conducted by Stanford Health Care, researchers achieved a 46% reduction in opioid use among 443 patients with cancer who underwent a range of urologic surgeries without increasing their pain or anxiety. They achieved this reduction through a two-pillared approach: (1) maximizing the use...
